Kyle Lefkoff is the Founder and General Partner of Boulder Ventures. In his thirty-seven years as a venture capitalist, Mr. Lefkoff has invested in 62 Colorado companies.
Mr. Lefkoff’s life science investments include Hauser Chemical Research (NASDAQ: HAUS); NeXstar Pharmaceuticals (sold to Gilead Sciences), Array BioPharma (sold to Pfizer), Dharmacon (sold to Fisher Scientific), Genomica (sold to Exelixis), ARCA Biopharma (NASDAQ: ABIO), miRagen Therapeutics (NASDAQ: MGEN), ArcherDX (sold to Invitae), and Mineralys.
His information technology investments include McData (sold to EMC); Atlantes Corp. (sold to Metromail); Compatible Systems Corp. (sold to Cisco Systems); Wall Street on Demand (sold to Goldman Sachs), Lefthand Networks (sold to HP), Linerate Systems (sold to F5), and Black Bear Energy.
Mr. Lefkoff founded Array BioPharma in May 1998 with Marv Caruthers and a group of Amgen scientists. Mr. Lefkoff was the Chairman of the Board of Array from its inception through August 2018, when Array’s targeted therapy for melanoma was approved by the FDA. In July 2019, Array was acquired by Pfizer for $11.8 billion in cash, the largest acquisition of a venture-backed life sciences company in the history of Colorado.
He is a Director of Black Bear Energy and the Holder’s Representative for the former Shareholders of ArcherDX.
Mr. Lefkoff received his B.A. in Economics from Vassar College (summa cum laude) in 1981. In 1980, Mr. Lefkoff completed a Fellowship in Economic History at the London School of Economics. In 1985, he completed his MBA in Finance at the University of Chicago.
An experienced alpinist and mountain guide, Mr. Lefkoff was the founding Chairman of the Board of the American Institute for Avalanche Research and Education (AIARE), the avalanche education standard among mountain guides and snow professionals in the USA. He was a member of the 1986 American Expedition to the North Face of K2.